For decades, ultrasound has been used to image organs such as the heart and kidneys, check blood flow, monitor the development of fetuses, reduce pain and even break up kidney stones.
Now, a Norwegian biotech company called Phoenix Solutions AS is working with the Translational Genomics Research Institute (TGen), a Phoenix, Arizona-based biomedical research facility, to test the use of these pulsed sound waves to direct and focus cancer drug therapies.
In laboratory tests, TGen will help analyze the effectiveness of a technology called Acoustic Cluster Therapy (ACT), a unique approach to targeting cancer cells by concentrating the delivery of chemotherapies, making them more effective and potentially reducing their toxicity.
Humanscan Co. Ltd., a South Korean manufacture of ultrasound diagnostic imaging, is developing clinically applicable hardware optimized for ACT, which TGen will then validate.
Phoenix Solutions is using funding from Innovation Norway to conduct this research in advance of pancreatic cancer clinical trials planned later this year.
“We are very pleased to receive this grant, which will enable us to develop and validate an optimal ultrasound platform for clinical use of ACT. In their respective fields, Humanscan and TGen both represent the cutting edge of science, and we are confident this will contribute to the clinical success of our program,” said Dr. Per Sontum, CEO of Phoenix Solutions.
TGen is a world leader in the development of novel therapeutics for the treatment of pancreatic cancer. The TGen team led the clinical development of one of the current standard-of-care regimens for this disease — nab-paclitaxel plus gemcitabine. TGen currently is involved in 13 pancreatic cancer clinical programs.
“We are pleased that this research program has become a reality, and look forward to working with ACT. The concept represents a novel approach to targeted drug delivery and looks very promising,” said Dr. Haiyong Han, a Professor in TGen’s Molecular Medicine Division and head of the Basic Research Unit in TGen’s Pancreatic Cancer Program.
Among the advantages of ultrasound technology: it is generally painless; non-invasive; does not require needles, injections or incisions; and patients are not exposed to ionizing radiation, making the procedure safer than diagnostic techniques such as X-rays and CT scans.
Humanscan CEO Sungmin Rhim said, “We are excited to enter into this collaboration with Phoenix (Solutions) and participate in the development of ACT. Ultrasound mediated, targeted drug delivery is an emerging therapy approach with great potential and we are delighted to be in the forefront of this development.”
Phoenix Solutions also is considering this technology for use in addressing other types of cancer, including: liver, prostate and triple-negative breast cancer; and other diseases, including those involving inflammation and the central nervous system.
The Latest on: Cancer drug delivery
via Google News
The Latest on: Cancer drug delivery
- Novel Drug Delivery Systems in Cancer Therapy Market Is Fueled by the Rising Number of People Suffering from Various Types of Cancer on November 12, 2018 at 10:48 am
Albany, NY -- (SBWIRE) -- 11/12/2018 -- The world is witnessing a continuous rise in the incidence of various types of cancer. Clinical benefits of embolic agents and nanoparticles over other therapy ... […]
- Two-cells-in-one combo therapy could bolster leukemia treatment on November 2, 2018 at 7:19 am
UCLA Samueli School of Engineering. (2018, October 31). Two-cells-in-one combo therapy could bolster leukemia treatment: A new delivery system guides drugs directly to cancer cells in bone marrow. Sci... […]
- Researchers design delivery system to guide drugs directly to cancer cells 'hiding' in bone marrow on October 30, 2018 at 5:57 am
A scanning electron microscope colorized to show the hematopoietic stem cells (purple) and blood platelets (green) joined together. Credit: Zhen Gu Research Lab/UCLA Researchers led by a UCLA ... […]
- New computer model designs a drug delivery strategy to fight cancer on October 29, 2018 at 12:09 pm
Researchers from Michigan State University and Stanford University have created a computer simulation, validated by experimental results, to help design drug-delivery nanoparticles that carry cancer-f... […]
- Are dendrimers the new age anti-cancer drug delivery agents? on October 25, 2018 at 1:25 am
As there are several limitations for designing an ideal anti-cancer drug, it is very difficult for modern scientists and researchers to fabricate a formulation for a complete optimized drug which can ... […]
- CERENIS to Present New Data Validating HDL Targeted Drug Delivery in the Field of Oncology and Immuno-Oncology at the 30th EORTC/NCI/AACR1 Symposium on October 22, 2018 at 9:13 am
was demonstrated to be very effective for intra tumor drug delivery and thus able to show marked inhibition of breast cancer tumor cell growth. These results for HDL and Cargomers® targeted drug deliv... […]
- New computer model designs a drug delivery strategy to fight cancer on October 3, 2018 at 1:34 pm
A better understanding of how nanoparticles move from the bloodstream into a tumor could eventually lead to more effective cancer treatment. Stanford researchers have created a computer simulation, va... […]
- X-rays burst chemo-filled nanobubbles for targeted cancer drug delivery on September 10, 2018 at 7:43 pm
A new potential cancer treatment uses nanobubbles called liposomes to ... "Liposomes are already well established as an extremely effective drug-delivery system," says Wei Deng, lead author of the stu... […]
- Ultrasound remotely bursts heat-sensitive capsules, delivering drugs directly to tumors on September 4, 2018 at 11:40 pm
A promising new cancer drug delivery system has successfully passed early human safety trials. The treatment delivers cancer drugs in heat-activated capsules to tumors in the liver and then uses a foc... […]
via Bing News